Serveur d'exploration Covid (26 mars)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE.

Identifieur interne : 001339 ( Main/Exploration ); précédent : 001338; suivant : 001340

A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE.

Auteurs : Dirk Jochmans [Belgique] ; Pieter Leyssen ; Johan Neyts

Source :

RBID : pubmed:22575574

Descripteurs français

English descriptors

Abstract

For antiviral screenings purposes, infection of cell cultures with the virus under study, should ideally result in the induction, within just a few days, of (nearly) complete CPE and allow the calculation of acceptable Z' factors (>0.5). The human Corona virus NL63 (HCoV-NL63) causes only limited CPE on different cell lines (Schildgen et al., 2006). Following infection of Vero118 cells, virus-induced CPE was too low to allow readout based on classical colorimetric methods (such as the MTS assay), even following prolonged incubation times (>7 days). To develop an antiviral screenings-assay against HCoV-NL63, we explored whether a dead-cell protease substrate could be used instead. The substrate used is a quenched peptide (bis-AAF-R110) that releases a fluorophore upon proteolytic-cleavage by proteases; the latter released from dead cells. Following different rounds of optimization a screening protocol was developed: Vero118 cells in 96-well plate format were infected with HCoV-NL63 (MOI=0.01; 200μL cell culture; 2.10(4)cells/mL, IMDM 5% FBS medium). Cultures were subsequently incubated for 5 days at 35°C after which 20μL of the peptide solution was added. Fluorescence was quantitated 2 hr after incubation at 37°C. A roughly 3-fold increase in fluorescence intensity in the infected cultures was observed as compared to the uninfected cultures with a low well-to-well variability. Z' factors calculated from different experiments were in the range of 0.6-0.8, indicating excellent assay quality. An anti-ACE2 polyclonal antiserum (that prevents coronavirus infection in cell cultures) was used as a positive control and allowed to validate the assay for antiviral screening purposes. In conclusion, in conditions where a viability staining is inadequate to quantitate virus-induced CPE, a novel simple and convenient method that detects cell-death and that is suitable for high-throughput screening purposes can be employed.

DOI: 10.1016/j.jviromet.2012.04.011
PubMed: 22575574


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE.</title>
<author>
<name sortKey="Jochmans, Dirk" sort="Jochmans, Dirk" uniqKey="Jochmans D" first="Dirk" last="Jochmans">Dirk Jochmans</name>
<affiliation wicri:level="1">
<nlm:affiliation>Rega Institute for Medical Research, University of Leuven (KU Leuven), Leuven, Belgium. dirk.jochmans@rega.kuleuven.be</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Rega Institute for Medical Research, University of Leuven (KU Leuven), Leuven</wicri:regionArea>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Leyssen, Pieter" sort="Leyssen, Pieter" uniqKey="Leyssen P" first="Pieter" last="Leyssen">Pieter Leyssen</name>
</author>
<author>
<name sortKey="Neyts, Johan" sort="Neyts, Johan" uniqKey="Neyts J" first="Johan" last="Neyts">Johan Neyts</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22575574</idno>
<idno type="pmid">22575574</idno>
<idno type="doi">10.1016/j.jviromet.2012.04.011</idno>
<idno type="wicri:Area/PubMed/Corpus">000D16</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D16</idno>
<idno type="wicri:Area/PubMed/Curation">000D16</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D16</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000D03</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D03</idno>
<idno type="wicri:Area/Ncbi/Merge">000323</idno>
<idno type="wicri:Area/Ncbi/Curation">000323</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000323</idno>
<idno type="wicri:Area/Main/Merge">001341</idno>
<idno type="wicri:Area/Main/Curation">001339</idno>
<idno type="wicri:Area/Main/Exploration">001339</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE.</title>
<author>
<name sortKey="Jochmans, Dirk" sort="Jochmans, Dirk" uniqKey="Jochmans D" first="Dirk" last="Jochmans">Dirk Jochmans</name>
<affiliation wicri:level="1">
<nlm:affiliation>Rega Institute for Medical Research, University of Leuven (KU Leuven), Leuven, Belgium. dirk.jochmans@rega.kuleuven.be</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Rega Institute for Medical Research, University of Leuven (KU Leuven), Leuven</wicri:regionArea>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Leyssen, Pieter" sort="Leyssen, Pieter" uniqKey="Leyssen P" first="Pieter" last="Leyssen">Pieter Leyssen</name>
</author>
<author>
<name sortKey="Neyts, Johan" sort="Neyts, Johan" uniqKey="Neyts J" first="Johan" last="Neyts">Johan Neyts</name>
</author>
</analytic>
<series>
<title level="j">Journal of virological methods</title>
<idno type="eISSN">1879-0984</idno>
<imprint>
<date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Cell Death</term>
<term>Cell Survival</term>
<term>Chlorocebus aethiops</term>
<term>Coronavirus NL63, Human (drug effects)</term>
<term>Coronavirus NL63, Human (physiology)</term>
<term>Fluorescent Dyes (chemistry)</term>
<term>High-Throughput Screening Assays</term>
<term>Host-Pathogen Interactions</term>
<term>Humans</term>
<term>Peptides (chemistry)</term>
<term>Proteolysis</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cellules Vero</term>
<term>Colorants fluorescents ()</term>
<term>Coronavirus humain NL63 ()</term>
<term>Coronavirus humain NL63 (physiologie)</term>
<term>Humains</term>
<term>Interactions hôte-pathogène</term>
<term>Mort cellulaire</term>
<term>Peptides ()</term>
<term>Protéolyse</term>
<term>Survie cellulaire</term>
<term>Tests de criblage à haut débit</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en">
<term>Fluorescent Dyes</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Coronavirus NL63, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Coronavirus humain NL63</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Coronavirus NL63, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Cell Death</term>
<term>Cell Survival</term>
<term>Chlorocebus aethiops</term>
<term>High-Throughput Screening Assays</term>
<term>Host-Pathogen Interactions</term>
<term>Humans</term>
<term>Proteolysis</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Cellules Vero</term>
<term>Colorants fluorescents</term>
<term>Coronavirus humain NL63</term>
<term>Humains</term>
<term>Interactions hôte-pathogène</term>
<term>Mort cellulaire</term>
<term>Peptides</term>
<term>Protéolyse</term>
<term>Survie cellulaire</term>
<term>Tests de criblage à haut débit</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">For antiviral screenings purposes, infection of cell cultures with the virus under study, should ideally result in the induction, within just a few days, of (nearly) complete CPE and allow the calculation of acceptable Z' factors (>0.5). The human Corona virus NL63 (HCoV-NL63) causes only limited CPE on different cell lines (Schildgen et al., 2006). Following infection of Vero118 cells, virus-induced CPE was too low to allow readout based on classical colorimetric methods (such as the MTS assay), even following prolonged incubation times (>7 days). To develop an antiviral screenings-assay against HCoV-NL63, we explored whether a dead-cell protease substrate could be used instead. The substrate used is a quenched peptide (bis-AAF-R110) that releases a fluorophore upon proteolytic-cleavage by proteases; the latter released from dead cells. Following different rounds of optimization a screening protocol was developed: Vero118 cells in 96-well plate format were infected with HCoV-NL63 (MOI=0.01; 200μL cell culture; 2.10(4)cells/mL, IMDM 5% FBS medium). Cultures were subsequently incubated for 5 days at 35°C after which 20μL of the peptide solution was added. Fluorescence was quantitated 2 hr after incubation at 37°C. A roughly 3-fold increase in fluorescence intensity in the infected cultures was observed as compared to the uninfected cultures with a low well-to-well variability. Z' factors calculated from different experiments were in the range of 0.6-0.8, indicating excellent assay quality. An anti-ACE2 polyclonal antiserum (that prevents coronavirus infection in cell cultures) was used as a positive control and allowed to validate the assay for antiviral screening purposes. In conclusion, in conditions where a viability staining is inadequate to quantitate virus-induced CPE, a novel simple and convenient method that detects cell-death and that is suitable for high-throughput screening purposes can be employed.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Belgique</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Leyssen, Pieter" sort="Leyssen, Pieter" uniqKey="Leyssen P" first="Pieter" last="Leyssen">Pieter Leyssen</name>
<name sortKey="Neyts, Johan" sort="Neyts, Johan" uniqKey="Neyts J" first="Johan" last="Neyts">Johan Neyts</name>
</noCountry>
<country name="Belgique">
<noRegion>
<name sortKey="Jochmans, Dirk" sort="Jochmans, Dirk" uniqKey="Jochmans D" first="Dirk" last="Jochmans">Dirk Jochmans</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001339 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001339 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV2
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:22575574
   |texte=   A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:22575574" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidV2 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Sat Mar 28 17:51:24 2020. Site generation: Sun Jan 31 15:35:48 2021